Drug Repurposing: Far Beyond New Targets for Old Drugs
- 2k Downloads
Repurposing drugs requires finding novel therapeutic indications compared to the ones for which they were already approved. This is an increasingly utilized strategy for finding novel medicines, one that capitalizes on previous investments while derisking clinical activities. This approach is of interest primarily because we continue to face significant gaps in the drug–target interactions matrix and to accumulate safety and efficacy data during clinical studies. Collecting and making publicly available as much data as possible on the target profile of drugs offer opportunities for drug repurposing, but may limit the commercial applications by patent applications. Certain clinical applications may be more feasible for repurposing than others because of marked differences in side effect tolerance. Other factors that ought to be considered when assessing drug repurposing opportunities include relevance to the disease in question and the intellectual property landscape. These activities go far beyond the identification of new targets for old drugs.
Key wordsdrug repurposing drug–target interactions intellectual property side effect tolerance target identification
This work was supported, in part, by NIH grants 5R21GM095952-02 and 5U54MH084690-04 (TIO) and by the Spanish Instituto de Salud Carlos III (JM) through the Drugs4Rare project within the framework of the International Rare Disease Research Consortium.
- 1.Oprea TI. Sense and nonsense in drug discovery: a chemical perspective. In: Kruse CG, Timmerman H, editors. Towards drugs of the future. Amsterdam: IOS Press; 2008. p. 29–36.Google Scholar
- 15.Celebrex® (celecoxib) capsules package information, http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d52185d-421f-4e34-8db7-f7676db2a226
- 16.Merck & Co., Inc. Merck announces voluntary worldwide withdrawal of Vioxx® (press release) Whitehouse Station, NJ; 2004 Sep 30.Google Scholar
- 18.PDSP (Psychoactive Drugs Screening Program) certified data, http://pdsp.med.unc.edu/pdsp.php?knowID=&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=celecoxib&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query
- 32.Wermuth CG. The ‘SOSA’ approach: an alternative to high-throughput screening. Med Chem Res. 2001;10:431–9.Google Scholar
- 33.Curley D, Easey A. Drug repurposing and repatenting. Bio-Science Law Review. 2009;10:131–4.Google Scholar